Atrial Fibrillation: Bleeding Risk Reduced by New Drug | Study Findings
Patients with atrial fibrillation can breathe a sigh of relief: A new anticoagulant, a Factor XI inhibitor, drastically lowers the risk of bleeding, according to recent study findings. This innovative drug, abelacimab, demonstrated superior safety compared to standard treatments like rivaroxaban in the AZALEA-TIMI 71 Study, significantly reducing the instances of bleeding requiring medical attention. The study showed extraordinary reductions in gastrointestinal bleeding, a common concern with current anticoagulants, offering a much-needed breakthrough for those battling AFib and dealing with secondary_keyword stroke risk. News directory 3 reports that researchers are optimistic, given the potential for safer stroke prevention. Eager to know what the next phase holds? Discover what’s next …
New Anticoagulant Shows promise in Reducing Bleeding Risk for AFib Patients
Updated June 13, 2025
A novel anticoagulant drug, abelacimab, is showing promise in significantly reducing bleeding risk for patients with atrial fibrillation (AFib), according to a study published in the New England Journal of Medicine. The drug, a Factor XI inhibitor, was evaluated in the AZALEA-TIMI 71 Study, which was halted early due to its overwhelming safety profile compared to standard treatments.
Atrial fibrillation,a common heart condition,affects approximately one in three individuals. It elevates the risk of stroke due to blood clot formation in the heart, which can than travel to the brain. While anticoagulants are typically prescribed to mitigate this risk, concerns about bleeding complications often lead to undertreatment or discontinuation of these medications.
The AZALEA-TIMI 71 Study, involving 1,287 participants across 95 global sites, compared abelacimab to rivaroxaban, a standard-of-care anticoagulant. Results indicated that a 150 mg dose of abelacimab reduced bleeding requiring hospitalization or medical attention by 62% compared to rivaroxaban. A 90 mg dose showed a 69% reduction in similar bleeding events. Notably, both doses of abelacimab nearly eliminated gastrointestinal bleeding, a common side effect of existing anticoagulants.
Researchers noted that stroke rates were low in the study, with no significant differences between the abelacimab and rivaroxaban groups. However, the trial was not specifically designed to assess ischemic events.
Christian Ruff, MD, MPH, director of General Cardiology at Brigham and Women’s Hospital and principal investigator of the AZALEA-TIMI 71 Study, emphasized the potential impact of Factor XI inhibitors.”It should be enormously satisfying to the cardiovascular field, patients and providers that Factor XI inhibitors live up to their promise of superior safety,” Ruff said. He added that bleeding complications from current anticoagulants contribute to significant undertreatment of AFib, making this a crucial advancement in cardiovascular care. This new anticoagulant may offer a safer alternative for stroke prevention in atrial fibrillation patients, addressing a critical unmet need in cardiovascular medicine.
“It should be enormously satisfying to the cardiovascular field, patients and providers that factor XI inhibitors live up to their promise of superior safety,” said Christian Ruff, MD, MPH.
What’s next
the TIMI Study Group is currently conducting a phase 3 trial, LILAC-TIMI 76, comparing a 150 mg dose of abelacimab to placebo in high-risk AFib patients ineligible for current anticoagulants. This trial aims to assess the drug’s effectiveness in preventing ischemic stroke and systemic embolism.